Best GLP-1 for Weight Loss: What the 2025 Data Shows

2025 GLP-1 Rankings for Weight Loss

Based on the latest clinical trial data, real-world evidence, and meta-analyses, here are our rankings for GLP-1 medications for weight loss in 2025:

Head-to-Head Comparison

For detailed cost comparisons, see our complete GLP-1 cost guide.

Our Comparison Methodology

Ranking GLP-1 medications requires looking beyond a single metric. Weight loss percentage grabs headlines, but the medication that produces the most average weight loss in a clinical trial is not automatically the best choice for every patient. Our 2025 rankings integrate several data sources and evaluation criteria to give a more complete picture of how these medications perform across different dimensions.

We began by reviewing the pivotal Phase 3 trials for each medication, including the STEP program for semaglutide, SURMOUNT for tirzepatide, and SCALE for liraglutide. These trials provide the gold-standard evidence for efficacy and safety, but they are conducted in controlled environments with selected patient populations. To complement trial data, we examined real-world evidence from electronic health record analyses, pharmacy claims databases, and published observational cohorts. Real-world data often shows more modest weight loss than clinical trials, but it reflects how medications perform outside of research settings where adherence, dose titration, and follow-up are less tightly managed.

Beyond raw efficacy, our methodology weights several additional factors. Tolerability matters because a medication that produces excellent weight loss but causes intolerable side effects leading to discontinuation is not practically effective. We considered discontinuation rates, the severity and duration of gastrointestinal side effects, and how quickly patients can titrate to therapeutic doses. Cardiovascular safety data plays a role as well, particularly the SELECT trial results for semaglutide, which demonstrated a 20% reduction in major adverse cardiovascular events. Tirzepatide's dedicated cardiovascular outcome trial, SURPASS-CVOT, reported results in 2025, meeting its primary endpoint against the active comparator dulaglutide in patients with type 2 diabetes; placebo-controlled outcome data in patients without diabetes, like semaglutide's SELECT trial, remains a distinguishing factor.

Accessibility and cost also factor into our rankings. A medication that most patients cannot afford or access provides limited real-world value regardless of its clinical trial performance. We evaluated insurance coverage rates, out-of-pocket costs, manufacturer savings program availability, and whether compounded alternatives exist. Finally, we considered the breadth of evidence, including how long a medication has been on the market, the volume of published research, the diversity of populations studied, and the availability of long-term follow-up data. Medications with deeper evidence bases provide greater confidence in their safety and efficacy profiles.

Matching Medications to Patient Profiles

The best GLP-1 medication for any individual depends on their specific clinical profile, health goals, and practical circumstances. Rather than asking which medication is objectively best, the more useful question is which medication best fits a particular patient. Understanding how different profiles align with different medications can help patients and providers make more informed decisions together.

Patients with higher starting BMI values, particularly those with a BMI above 40 or those with significant obesity-related comorbidities, may benefit most from tirzepatide. The SURMOUNT-1 trial showed that patients with higher baseline BMIs tended to lose a greater absolute amount of weight on tirzepatide, and the dual GIP/GLP-1 mechanism appears to provide additional metabolic benefits that are particularly valuable in patients with more severe metabolic disease. However, access to tirzepatide can be more limited due to cost and insurance coverage constraints.

Patients with established cardiovascular disease or significant cardiovascular risk factors have a strong evidence-based argument for semaglutide. The SELECT trial specifically enrolled patients with pre-existing cardiovascular disease and demonstrated meaningful reductions in heart attacks, strokes, and cardiovascular death. SELECT enrolled patients with overweight or obesity and established cardiovascular disease but without diabetes, a population where tirzepatide does not yet have comparable placebo-controlled outcome data, so semaglutide holds a distinct evidence advantage for this group. Patients with Type 2 diabetes who need dual management of weight and blood sugar may find either semaglutide or tirzepatide appropriate, though tirzepatide has shown greater A1c reductions in head-to-head comparisons.

For patients who are sensitive to gastrointestinal side effects or who have had difficulty tolerating other GLP-1 medications, liraglutide may serve as a gentler starting point. Its daily dosing allows for more granular dose adjustments, and its shorter half-life means that if side effects do occur, they may resolve more quickly after a dose reduction. Some clinicians use liraglutide as a bridge medication, starting patients on daily dosing to establish tolerability before transitioning to a weekly injectable if greater efficacy is needed.

Insurance, Cost, and Affordability Factors

The financial landscape for GLP-1 medications in 2025 remains one of the biggest barriers to treatment. List prices for brand-name medications range from approximately $900 to $1,350 per month, but the actual cost a patient pays varies enormously depending on their insurance status, plan design, and ability to access savings programs. Understanding these financial dynamics is essential for making a practical medication choice rather than a purely clinical one.

Commercial insurance coverage for GLP-1 weight loss medications has expanded significantly since the publication of the SELECT cardiovascular outcomes data. Many large employers and commercial plans now cover Wegovy or Zepbound, though often with prior authorization requirements, step therapy protocols, or BMI thresholds. Patients should review their specific formulary and contact their plan to understand what criteria must be met before coverage is approved. Prior authorization typically requires documentation of BMI, comorbidities, and sometimes evidence of prior weight loss attempts through diet and exercise.

Medicare Part D did not cover anti-obesity medications as of early 2025, leaving millions of older Americans without coverage. The Treat and Reduce Obesity Act would change this exclusion, but as of early 2025 it had not been enacted. Medicaid coverage varies by state, with some state programs covering GLP-1 medications for weight loss and others maintaining exclusions. Patients on government insurance should check their specific plan and consider manufacturer patient assistance programs if they meet income eligibility requirements.

For patients paying out of pocket, compounded semaglutide remains the most affordable pathway; it is prepared per individual prescription by a state-licensed 503A compounding pharmacy and is not itself FDA-approved as a drug. Compounded tirzepatide is more limited in availability and generally more expensive. Manufacturer savings cards from both Novo Nordisk and Eli Lilly can reduce costs significantly for commercially insured patients, sometimes bringing monthly costs below $25. However, these savings cards have eligibility restrictions and typically exclude patients with government insurance. When comparing total cost of treatment, patients should also factor in consultation fees, lab monitoring, and injection supplies, as these vary between providers and are not always included in the quoted medication price.

Emerging and Pipeline Options to Watch

The GLP-1 medication landscape is evolving rapidly, with several next-generation therapies in late-stage clinical development that may reshape the rankings in 2026 and beyond. Understanding what is in the pipeline helps patients and providers plan ahead and set appropriate expectations about future options that may offer improved efficacy, convenience, or affordability.

Oral formulations represent a major area of development. Oral semaglutide for weight loss at higher doses (50 mg daily) has shown promising results in the OASIS trial program, with weight loss approaching that of injectable semaglutide. If these oral options achieve comparable efficacy to injectables, they could dramatically expand access by eliminating the injection barrier that deters some patients from starting treatment. Orforglipron, a small-molecule oral GLP-1 agonist from Eli Lilly, represents yet another approach. Unlike oral semaglutide, which is a peptide requiring special formulation to survive the digestive tract, orforglipron is a non-peptide molecule that may be easier to manufacture at scale, potentially lowering costs. In the Phase 3 ATTAIN-1 trial, reported in 2025, orforglipron produced approximately 12.4% average weight loss at 72 weeks at its highest dose.

CagriSema, developed by Novo Nordisk, combines semaglutide with cagrilintide, an amylin analog. Early data suggests this combination produces greater weight loss than semaglutide alone, potentially narrowing or closing the efficacy gap between semaglutide and tirzepatide. Amylin works through complementary appetite suppression pathways, and the combination approach may provide a more comprehensive metabolic effect. In the Phase 3 REDEFINE-1 trial, CagriSema produced approximately 22.7% average weight loss at 68 weeks, confirming greater efficacy than semaglutide alone and clarifying where CagriSema fits relative to existing options.

Choosing the Right GLP-1 for You

Next-Generation Options: 2025 Trial Readouts

Frequently Asked Questions